GlassScriptPhysician profile
Allison Cothern
NPI 1013539832
$6,316.73
in general payments reported to CMS, 2019-2025
47 companies · $1,495 in 2025
The $1,495 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $338 · 2022: $2,164 · 2023: $1,376 · 2024: $944 · 2025: $1,495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,814.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $786.88 | 2021-2025 | |
| Novo Nordisk INC | $770.39 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $556.68 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $396.38 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $307.64 | 2021-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $282.97 | 2023-2025 | Rexulti |
| Pfizer INC. | $276.44 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.17 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $225.83 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $211.02 | 2021-2025 | Repatha, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $193.04 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $166.41 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Dexcom, INC. | $147.37 | 2023-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $136.55 | 2023-2025 | Veozah, Myrbetriq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $120.01 | 2022-2025 | Caplyta |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Cothern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.